Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

expense (22,889) (22,499)

Research and development expense (12,585) (12,312)

Total pre-tax charges for stock-

based compensation expense (41,988) (40,707)

Tax benefit 12,537 12,432

Stock-based compensation expense,

net of tax $(29,451) $(28,275)

Diluted earnings per share and diluted weighted average shares outstanding

for the three months ended March 31, 2008 and 2007 were computed according

to the provisions of FAS 123R.

(2) Includes a charge of $(69,900)K recorded in February 2008 representing

the premium paid to purchase five million shares of Isis

Pharmaceuticals, Inc. common stock.

(3) For the three months ended March 31, 2007, includes a pre-tax gain of

$10,848K related to the sale of our entire investment in the common

stock of Therapeutic Human Polyclonals, Inc. in March 2007, which had

a zero cost basis.

(4) All periods reflect the adoption of Emerging Issues Task Force Issue

No. 04-8, "The Effect of Contingently Convertible Debt on Diluted

Earnings Per Share," or EITF 04-8. As a result of the adoption of EITF

04-8, the 9,686K shares issuable upon conversion of our $690.0 million

in principal of 1.25% convertible senior notes, which were issued in

December 2003, are now included in diluted weighted average shares

outstanding for purposes of computing diluted earnings per share,

unless the effect would be anti-dilutive. In accordance with EITF 04-

8, interest and debt fees related to these notes of $1.9 million, net

of tax, for both the three months ended March 31, 2008 and 2007, have

been added back to net income and 9,686K shares have
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... December 19, 2014 In contrast to ... LEDs with various colors, Valoya uses proprietary LED technology ... offers best possible uniformity which is critical in low ... high spectral accuracy throughout its lifetime which is up ... tubes. , "The investment cost was clearly higher ...
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Committee Recommendation in European UnionSAN MATEO, Calif., March 19 ... biopharmaceutical company focused on developing and commercializing novel pain ... call on Friday, March 20, 2009 at 9:00 a.m. ... year-end 2008 results and the European Medicines Agency,s (EMEA) ...
... Solutions, a global life sciences technology solutions company ... that one of the world,s largest pharmaceutical companies ... System. This system provides a powerful, flexible ... lifecycle... from proposal to publication... helping to ensure ...
... will allow the recycling and conversion of 60% ... 19 /PRNewswire/ - Enerkem Inc., a leading advanced ... its plans to build and operate a second-generation ... In addition, the company announced the signature of ...
Cached Biology Technology:NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 2NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 4Top Ten Pharma Company Deploys MedNet Solutions' Investigator Initiated Trial Management System 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 3
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... release is available in German . ... and oxygen in order to survive. For this reason, a tumour ... to the blood circulation. In doing this, it is supported by ... neutrophils, which are supposed to protect the body against pathogens. ...
... poisoning in the news, including a recent event that led ... drives home the need for better bacterial detection long before ... the horizon is a new approach for pathogen screening that ... the technique in the ACS journal Analytical Chemistry . ...
... Nutrition Research Centre (CNRC) -- a $20 million ... (A*STAR) and National University Health Systems (NUHS) -- ... conduct nutritional studies to understand the causes of metabolic ... and formulate diets that can reduce the risks of ...
Cached Biology News:Jamming in tumors 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 3Asia's first under-1-roof Nutritional Research Centre set up in Singapore 4
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... are custom designed to meet your needs. ... 8,455 features per array (2 arrays/1" x ... array (1 array/slide). Features ... - This extended length delivers higher sensitivity ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
Biology Products: